View in EDS HTML Full Text

Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration

Saved in:
Bibliographic Details
Title: Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration
Authors: National Comprehensive Cancer Network (NCCN)
Source: Business Wire (English). 10/15/2012.
Abstract: The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These grants were made possible through a research grant from AVEO Oncology and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs in the treatment of solid tumors. [ABSTRACT FROM PUBLISHER]
Database: Regional Business News
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: bwh
DbLabel: Regional Business News
An: bizwire.c44646352
AccessLevel: 6
PubType: News
PubTypeId: newspaperArticle
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22National+Comprehensive+Cancer+Network+%28NCCN%29%22">National Comprehensive Cancer Network (NCCN)</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Business+Wire+%28English%29%22">Business Wire (English)</searchLink>. 10/15/2012.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These grants were made possible through a research grant from AVEO Oncology and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs in the treatment of solid tumors. [ABSTRACT FROM PUBLISHER]
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=bwh&AN=bizwire.c44646352
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: National Comprehensive Cancer Network (NCCN)
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 10
              Text: 10/15/2012
              Type: published
              Y: 2012
          Titles:
            – TitleFull: Business Wire (English)
              Type: main
ResultId 1